Quantum Genomics SA (ALQGC) - Total Assets
Based on the latest financial reports, Quantum Genomics SA (ALQGC) holds total assets worth €354.65K EUR (≈ $414.62K USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Quantum Genomics SA (ALQGC) net assets for net asset value and shareholders' equity analysis.
Quantum Genomics SA - Total Assets Trend (2009–2024)
This chart illustrates how Quantum Genomics SA's total assets have evolved over time, based on quarterly financial data.
Quantum Genomics SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Quantum Genomics SA's total assets of €354.65K consist of 99.6% current assets and 0.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 84.9% |
| Accounts Receivable | €27.44K | 7.7% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €1.05K | 0.3% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how Quantum Genomics SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ALQGC company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Quantum Genomics SA's current assets represent 99.6% of total assets in 2024, an increase from 70.5% in 2009.
- Cash Position: Cash and equivalents constituted 84.9% of total assets in 2024, up from 8.1% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 7.7% of total assets.
Quantum Genomics SA Competitors by Total Assets
Key competitors of Quantum Genomics SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Ascendis Pharma AS
F:A71
|
Germany | €1.30 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.69 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098
|
China | CN¥1.56 Billion |
Quantum Genomics SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.05 | 2.73 | 3.35 |
| Quick Ratio | 2.05 | 2.82 | 3.28 |
| Cash Ratio | 0.00 | 0.00 | 1.18 |
| Working Capital | €181.15K | €2.34 Million | €9.98 Million |
Quantum Genomics SA - Advanced Valuation Insights
This section examines the relationship between Quantum Genomics SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.21 |
| Latest Market Cap to Assets Ratio | 14.17 |
| Asset Growth Rate (YoY) | -90.5% |
| Total Assets | €354.65K |
| Market Capitalization | $5.03 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Quantum Genomics SA's assets at a significant premium (14.17x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Quantum Genomics SA's assets decreased by 90.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Quantum Genomics SA (2009–2024)
The table below shows the annual total assets of Quantum Genomics SA from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €354.65K ≈ $414.62K |
-90.53% |
| 2023-12-31 | €3.75 Million ≈ $4.38 Million |
-84.16% |
| 2022-12-31 | €23.66 Million ≈ $27.66 Million |
+11.37% |
| 2021-12-31 | €21.24 Million ≈ $24.83 Million |
-35.24% |
| 2020-12-31 | €32.80 Million ≈ $38.35 Million |
+121.95% |
| 2019-12-31 | €14.78 Million ≈ $17.28 Million |
-20.03% |
| 2018-12-31 | €18.48 Million ≈ $21.61 Million |
+32.79% |
| 2017-12-31 | €13.92 Million ≈ $16.27 Million |
-4.08% |
| 2016-12-31 | €14.51 Million ≈ $16.96 Million |
+37.65% |
| 2015-12-31 | €10.54 Million ≈ $12.32 Million |
+121.78% |
| 2014-12-31 | €4.75 Million ≈ $5.56 Million |
+180.76% |
| 2013-12-31 | €1.69 Million ≈ $1.98 Million |
+60.21% |
| 2012-12-31 | €1.06 Million ≈ $1.24 Million |
+24.25% |
| 2011-12-31 | €850.38K ≈ $994.19K |
+0.53% |
| 2010-12-31 | €845.89K ≈ $988.93K |
0.00% |
| 2009-12-31 | €845.90K ≈ $988.95K |
-- |
About Quantum Genomics SA
Quantum Genomics Société Anonyme is in the process of liquidation of its remaining assets. Previously, the company was engaged in the development of drugs to treat cardiovascular diseases. Quantum Genomics Société Anonyme was incorporated in 2005 and is headquartered in Paris, France.